ABSTRACT
INTRODUCTION
Gastroparesis is characterized by a failure of normal gastric motility and emptying. The delay in gastric emptying leads to considerable morbidity due to nausea, vomiting, anorexia, and stomach fullness. Both type 1 and 2 diabetes mellitus are frequently associated with abnormal gastric motility, 1,2 and are a recognized cause of gastroparesis. The relationship between delayed gastric emptying and symptoms is variable, and individuals with delayed gastric emptying may be asymptomatic. Cross-sectional studies show that around 30%-50% of those with type 1 and 2 diabetes exhibit delayed gastric emptying. 3, 4 Paradoxically, however, in the early stages of 2010 1 Dopamine is present in the gastrointestinal tract and inhibits gastrointestinal motility via the suppression of neuronal acetylcholine release by the D2 receptor. 14 This mechanism has been exploited therapeutically and forms the mainstay for therapeutic strategies using prokinetic agents. Additional alternative mechanisms include the direct effect of acute hyperglycemia causing a significant delay in gastric emptying, 15 by inducing motor dysfunction; therefore, improvement in glycemia can increase the rate of gastric emptying. 16 In both healthy subjects and patients with type 1 diabetes, acute changes in glycemia with a lowering of blood glucose has been shown to affect gastric motor function. 17, 18 Even physiological hyperglycemia of 8 mmol/L in healthy subjects and patients with type 1 diabetes may prolong the gastric emptying time when compared with ~4 mmol/L. This suggests that glycemic control has a major role in gastric motor dysfunction.
Other factors that may play an important role in altering gastric emptying are hyperinsulinemia and insulin resistance, body mass index (BMI), smoking, and gender. [19] [20] [21] [22] Table 2 , along with other prokinetic agents.
Erythromycin and Motilin Receptor Agonists
Erythromycin is a motilin receptor agonist that is associated with increased antral contractions with improved gastric emptying, 51, 52 particularly when administered intravenously. 
Ghrelin Agonists
Ghrelin is a recently discovered peptide that stimulates growth hormone release.
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It is synthesized in endocrine cells in the gastric mucosa [61] [62] [63] and is believed to exert the majority of its actions through the receptor 
Other Prokinetic Agents
Other agents include muscarinic agonists and anticholinesterases such as bethanechol and pyridostigmine, respectively, and may be used in DG, but data assessing effects on gastric emptying are lacking.
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MeChANICAL TheRApIeS
A number of nonpharmacological treatments have been used with varying success in the management of DG.
Acupuncture
The underlying mechanism of acupuncture in reducing symptoms of gastroparesis is unknown. 
Surgical Therapies
